Skip to main
IBIO

iBio (IBIO) Stock Forecast & Price Target

iBio (IBIO) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

iBio Inc. is leveraging advanced AI technologies to enhance the development and optimization of precision antibodies, which positions the company to mitigate downstream development risks effectively. The preclinical success of its amylin receptor agonist antibody, with significant reductions in food intake demonstrated in animal models, reflects strong therapeutic potential that could translate into marketable products. Furthermore, promising preclinical data for its lead candidate, IBIO-600, indicates favorable pharmacokinetic properties, including a long half-life, which could enhance its attractiveness for clinical advancement and commercialization.

Bears say

The analysis highlights significant uncertainties surrounding iBio Inc.'s prospects due to the potential development of alternative treatment methods that could make its therapies obsolete or non-competitive. Additionally, the company's reliance on the outcomes of ongoing clinical trials introduces considerable risk, as any failure to meet clinical endpoints could negatively impact share value. There are also concerns regarding possible regulatory disagreements with agencies like the EMA and FDA regarding the interpretation of preclinical and clinical trial data, which may further jeopardize the company’s standing in the biotechnology market.

iBio (IBIO) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of iBio and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About iBio (IBIO) Forecast

Analysts have given iBio (IBIO) a Buy based on their latest research and market trends.

According to 4 analysts, iBio (IBIO) has a Buy consensus rating as of Apr 23, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $4.75, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $4.75, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

iBio (IBIO)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.